TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38406850

Group type: EXPERIMENTAL
Intervention: 15 hours of in-home unsupervised game-based motor practice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: <5 hours of motor practice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: >10 hours of motor practice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: >30 hours of motor practice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: game-based motor practice
Number of subjects: 80
Study: 38407317

Group type: EXPERIMENTAL
Intervention: Tuvusertib (M1774) 180 mg QD (once daily), 2 weeks on/1 week off treatment
Number of subjects: 55
Study: 38407372

Group type: EXPERIMENTAL
Intervention: Standardised screenings for swallowing difficulties
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Non-oral route of medication administration
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Modification of solid medications (SMs)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Gugging Swallowing Screen
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Modified medication administration before specialist consultation
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Avoidance of whole SMs administration
Number of subjects: 195
Study: 38407394

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 38407508

Group type: EXPERIMENTAL
Intervention: Parsaclisib (5, 10, 15, 20, 30, and 45 mg once daily)
Number of subjects: 72
Study: 38407601

Group type: EXPERIMENTAL
Intervention: Zosuquidar (Zos) as a 72-h continuous intravenous infusion with chemotherapy (daunorubicin and cytarabine)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Zosuquidar (Zos) as a 72-h continuous intravenous infusion
Number of subjects: 106
Study: 38407610

Group type: EXPERIMENTAL
Intervention: HPA-1a immunised pregnancies
Number of subjects: 913

Group type: COMPARATOR
Intervention: HPA-1a-negative pregnancies (non-immunised)
Number of subjects: 913

Group type: COMPARATOR
Intervention: HPA-1a-positive pregnancies (randomly selected)
Number of subjects: 913
Study: 38407630

Group type: EXPERIMENTAL
Intervention: rhPSMA-10.1 and -10.2 radiolabeled with lutetium-177
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhPSMA-10.1 and -10.2
Number of subjects: 0
Study: 38407674

Group type: EXPERIMENTAL
Intervention: 5xSTS (Five-time sit-to-stand test)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: HerQLes (Hernia-Related Quality-of-Life survey)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: QUeST (Quiet Unstable Sitting Test)
Number of subjects: 77
Study: 38407697

Group type: EXPERIMENTAL
Intervention: Developmental Profile, 4th edition (DP-4) via telehealth
Number of subjects: 93

Group type: COMPARATOR
Intervention: Mullen Scales of Early Learning (MSEL) in-person testing
Number of subjects: 93
Study: 38407817

Group type: EXPERIMENTAL
Intervention: Septic ARDS patients
Number of subjects: 214

Group type: COMPARATOR
Intervention: Non-ARDS patients
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: ARDS nonsurvivors
Number of subjects: 214
Study: 38407848

Group type: EXPERIMENTAL
Intervention: Different interdialytic intervals
Number of subjects: 0
Study: 38407859

Group type: EXPERIMENTAL
Intervention: Viaskin milk 300 μg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Viaskin milk 300 μg (2 to 11 years age group)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (2 to 11 years age group)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Viaskin milk (all doses)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Viaskin milk 500 μg
Number of subjects: 198
Study: 38407871

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ascites
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cirrhotic patients without ascites
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with portal vein thrombosis (PVT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cirrhotic patients without portal vein thrombosis (PVT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Presence of portal vein thrombosis (PVT)
Number of subjects: 131
Study: 38407974

Group type: EXPERIMENTAL
Intervention: DNAase (0.1%) eye drops four times daily for 8 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vehicle (placebo) eye drops
Number of subjects: 58
Study: 38408060

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 1800mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (4.5mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 38408067

Group type: EXPERIMENTAL
Intervention: EMPOWER mobile app with health coaching and shared decision-making interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual primary care (Control)
Number of subjects: 0
Study: 38408215

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: PrEP (oral pre-exposure prophylaxis)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: HIVST and PrEP
Number of subjects: 911

Group type: COMPARATOR
Intervention: HIVST-alone
Number of subjects: 911

Group type: COMPARATOR
Intervention: PrEP-alone
Number of subjects: 911

Group type: COMPARATOR
Intervention: PrEP and HIVST
Number of subjects: 911
Study: 38408310

Group type: EXPERIMENTAL
Intervention: Virtual reality Pelli-Robson contrast sensitivity test
Number of subjects: 28

Group type: COMPARATOR
Intervention: In-office Pelli-Robson contrast sensitivity test
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Virtual reality Pelli-Robson test
Number of subjects: 28

Group type: COMPARATOR
Intervention: In-office test
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Virtual reality Pelli-Robson results
Number of subjects: 28
Study: 38408357

Group type: EXPERIMENTAL
Intervention: Baricitinib+remdesivir
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo+remdesivir
Number of subjects: 67
Study: 38408443

Group type: EXPERIMENTAL
Intervention: Topical Palmitoylethanolamide (Levagen+) applied twice daily for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard moisturiser (comparator) applied twice daily for 4 weeks
Number of subjects: 72
Study: 38408457

Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (1 mg/kg, 3 mg/kg, 7 mg/kg, 12 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (1 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (3 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (7 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody (12 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue monoclonal antibody
Number of subjects: 40
Study: 38408462

Group type: EXPERIMENTAL
Intervention: Enhanced strategy group (internal champion plus external supervision with audit and feedback)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Basic strategy group (internal champion alone)
Number of subjects: 589
Study: 38408702

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 658

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 658
Study: 38408725

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at early pregnancy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) at early pregnancy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Docosatetraenoic acid (DTA)
Number of subjects: 214
Study: 38408729

Group type: EXPERIMENTAL
Intervention: Daily consumption of a beverage sweetened with 25% of the ADI of stevia for 4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Daily consumption of a beverage sweetened with 30 g of sucrose for 4 weeks
Number of subjects: 59
Study: 38408861

Group type: EXPERIMENTAL
Intervention: Concordant measurement (CM)
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Concordant small measurement (CsM)
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Discordant smaller birth weight (sBW)
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Discordant smaller head circumference (sHC)
Number of subjects: 3473
Study: 38408943

Group type: EXPERIMENTAL
Intervention: Handsewn anastomoses (end-to-end or Kono-S)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Stapled anastomosis (side-to-side)
Number of subjects: 354
Study: 38408999

Group type: EXPERIMENTAL
Intervention: Zilovertamab in combination with paclitaxel
Number of subjects: 16
Study: 38409060

Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Upper limb motor therapy
Number of subjects: 50
Study: 38409075

Group type: EXPERIMENTAL
Intervention: Physical Activity Self-efficacy (PAS) intervention, an online behavioral intervention designed to promote physical activity.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care group (control group).
Number of subjects: 30
Study: 38409086

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care (without POCUS)
Number of subjects: 256
Study: 38409089

Group type: EXPERIMENTAL
Intervention: Pharmacist delivered QuitAid intervention (yes)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (NRT) gum + NRT patch
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8 weeks of NRT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard 4 weeks of NRT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pharmacist delivered QuitAid intervention (no)
Number of subjects: 24
Study: 38409129

Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy (BAT) + Pulmonary Rehabilitation (PR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 43
Study: 38409229

Group type: EXPERIMENTAL
Intervention: cfDNA-based NGS analysis (FoundationOne® Liquid CDx)
Number of subjects: 542
Study: 38409283

Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure (nICP) monitoring using an optical sensor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Invasive ICP monitoring
Number of subjects: 40
Study: 38409323

Group type: EXPERIMENTAL
Intervention: High protein intake (excess of ∼25 g per meal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein intake in excess of ∼22% of dietary energy requirements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leucine as a key activator of mTOR signalling
Number of subjects: 0
Study: 38409332

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cell (MSC) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 38410023

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 196
Study: 38410109

Group type: EXPERIMENTAL
Intervention: CC-3 bispecific CD276xCD3 antibody, starting dose of 50 µg, with potential increases up to 800 µg depending on safety review.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CC-3 bispecific CD276xCD3 antibody at maximum tolerated dose (MTD) after determination, additional 14 patients.
Number of subjects: 17
Study: 38410116

Group type: EXPERIMENTAL
Intervention: ELENAGEN (plasmid encoding p62/SQSTM1) in combination with gemcitabine (GEM) 1000 mg/m²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine (GEM) 1000 mg/m²
Number of subjects: 0
Study: 38410454

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 0
Study: 38410470

Group type: EXPERIMENTAL
Intervention: EEG coherence in LD toddlers
Number of subjects: 55

Group type: COMPARATOR
Intervention: EEG coherence in TD toddlers
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sleep spindle metrics in LD toddlers
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sleep spindle metrics in TD toddlers
Number of subjects: 55
Study: 38410567

Group type: EXPERIMENTAL
Intervention: S-HITHOC (cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy)
Number of subjects: 37
Study: 38410608

Group type: EXPERIMENTAL
Intervention: Consolidative hypofractionated radiation therapy (hfRT) using stereotactic body radiotherapy (SBRT) starting from 6.5 Gy ×2 fractions and escalating to 10 Gy ×2 fractions, delivered 1 to 2 months after dCRT and concurrently with durvalumab.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adjuvant anti-PD-L1 therapy using durvalumab, delivered concurrently with hfRT.
Number of subjects: 32
Study: 38410766

Group type: EXPERIMENTAL
Intervention: Children considered recovered by their parents following hospitalization with SARS-CoV-2-related conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children reported as not recovered
Number of subjects: 0
Study: 38410790

Group type: EXPERIMENTAL
Intervention: mHealth app-based self-management program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine care plus placebo app
Number of subjects: 96
Study: 38410920

Group type: EXPERIMENTAL
Intervention: Immunotherapy with durvalumab and tremelimumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Capecitabine with immunotherapy (durvalumab and tremelimumab)
Number of subjects: 40
Study: 38410942

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 453

Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 453
Study: 38410944

Group type: EXPERIMENTAL
Intervention: Elective percutaneous left ventricular unloading
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care (no planned mechanical circulatory support)
Number of subjects: 250
Study: 38410952

Group type: EXPERIMENTAL
Intervention: Acute myocardial injury defined as at least 1 high-sensitivity cardiac troponin T value above the upper reference limit (14 ng/L) with a rise/fall of >20%.
Number of subjects: 1067
Study: 38410945

Group type: EXPERIMENTAL
Intervention: Invasive management with angiography, revascularization, and guideline-directed medical therapy
Number of subjects: 5179

Group type: COMPARATOR
Intervention: Initial conservative management with guideline-directed medical therapy alone
Number of subjects: 5179

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 5179
Study: 38411017

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid during preconception and pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control supplement containing calcium, iodine, iron, β-carotene, and folic acid
Number of subjects: 0
Study: 38411246

Group type: EXPERIMENTAL
Intervention: Age Shock Index (ASI) ≥ 44
Number of subjects: 27312

Group type: EXPERIMENTAL
Intervention: Age Shock Index (ASI)
Number of subjects: 27312

Group type: COMPARATOR
Intervention: Shock Index (SI)
Number of subjects: 27312

Group type: COMPARATOR
Intervention: Global Registry of Acute Coronary Events (GRACE) score
Number of subjects: 27312

Group type: COMPARATOR
Intervention: Thrombolysis in Myocardial Infarction (TIMI) risk index
Number of subjects: 27312
Study: 38411348

Group type: EXPERIMENTAL
Intervention: Augmented Intelligence (AuI) skin cancer screening
Number of subjects: 205

Group type: COMPARATOR
Intervention: Artificial Intelligence (AI) skin cancer screening
Number of subjects: 205

Group type: COMPARATOR
Intervention: Dermatologist skin cancer screening
Number of subjects: 205

Group type: COMPARATOR
Intervention: 3D Total-Body Photography (3D-TBP)
Number of subjects: 205

Group type: COMPARATOR
Intervention: 2D Total-Body Photography (2D-TBP)
Number of subjects: 205

Group type: COMPARATOR
Intervention: AI assessment in dermatology
Number of subjects: 205

Group type: COMPARATOR
Intervention: AI assessment for beginners (<2 years' experience)
Number of subjects: 205

Group type: COMPARATOR
Intervention: AI assessment for experts (>5 years' experience)
Number of subjects: 205
Study: 38411644

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Medical/lifestyle management
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 262
Study: 38411949

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL) training, twice a week for 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 38411964

Group type: EXPERIMENTAL
Intervention: Bridge clinic
Number of subjects: 335

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 335
Study: 38411973

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir 1 gm daily for 1 year
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 527
Study: 38412008

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in people with diabetes
Number of subjects: 7139

Group type: COMPARATOR
Intervention: COVID-19 vaccination in people without diabetes
Number of subjects: 7139
Study: 38412047

Group type: EXPERIMENTAL
Intervention: EHR-based clinical decision support intervention for PrEP provision
Number of subjects: 5051

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5051

Group type: EXPERIMENTAL
Intervention: EHR-based intervention for HIV providers
Number of subjects: 5051

Group type: EXPERIMENTAL
Intervention: EHR-based intervention for non-HIV providers
Number of subjects: 5051
Study: 38412310

Group type: EXPERIMENTAL
Intervention: T-PGSadult
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: SHBG-PGSadult
Number of subjects: 109
Study: 38412408

Group type: EXPERIMENTAL
Intervention: Primary Tumor Resection (PTR)
Number of subjects: 393

Group type: COMPARATOR
Intervention: No Primary Tumor Resection (No PTR)
Number of subjects: 393
Study: 38412412

Group type: EXPERIMENTAL
Intervention: Binary amyloid positivity status
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Continuous amyloid standardized uptake value ratio
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Binary amyloid
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Continuous amyloid
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Global amyloid burden
Number of subjects: 510
Study: 38412437

Group type: EXPERIMENTAL
Intervention: Contemporary percutaneous coronary interventions for chronic total occlusion (CTO)
Number of subjects: 0
Study: 38412543

Group type: EXPERIMENTAL
Intervention: Triadic walking with culturally celebratory social reminiscence, 1-mile 3×/week for 6 months
Number of subjects: 42
Study: 38412573

Group type: EXPERIMENTAL
Intervention: Self-compassionate touch
Number of subjects: 135

Group type: COMPARATOR
Intervention: Finger-tapping active control
Number of subjects: 135
Study: 38412776

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting frailty trajectories
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 381
Study: 38412840

Group type: EXPERIMENTAL
Intervention: Concomitant crural repair during LSG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy alone (control)
Number of subjects: 0
Study: 38412900

Group type: EXPERIMENTAL
Intervention: Automated caries scoring system using TRIOS Patient Monitoring software
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional visual and radiographic assessment
Number of subjects: 91
Study: 38413147

Group type: EXPERIMENTAL
Intervention: Standard dose VKA targeting an international normalised ratio of 2.0-3.0
Number of subjects: 718

Group type: COMPARATOR
Intervention: No oral anticoagulation
Number of subjects: 718
Study: 38413153

Group type: EXPERIMENTAL
Intervention: Comprehensive immunophenotyping of the peripheral blood immune compartment and advanced neuroimaging markers of SVD and BBB permeability.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging to assess white matter microstructure.
Number of subjects: 200
Study: 38413157

Group type: EXPERIMENTAL
Intervention: LOCK Falls Programme, an evidence-based quality improvement intervention involving front-line care team huddles, data collection through observation, and communication facilitation.
Number of subjects: 8480

Group type: EXPERIMENTAL
Intervention: Staff survey conducted with 1200 staff members.
Number of subjects: 8480

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with 80 residents and 400 staff members.
Number of subjects: 8480
Study: 38413161

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heated Eye Mask (HEM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vectored Thermal Pulsation System (VTPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyelid Massage Device (EMD)
Number of subjects: 0
Study: 38413184

Group type: EXPERIMENTAL
Intervention: Virtual reality hypnosis (group VRH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (group control)
Number of subjects: 60
Study: 38413246

Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination therapy
Number of subjects: 35
Study: 38413410

Group type: EXPERIMENTAL
Intervention: Asunercept (APG101) treatment
Number of subjects: 12
Study: 38413420

Group type: EXPERIMENTAL
Intervention: DEB-TACE using epirubicin-loaded microspheres (≤ 100 μm)
Number of subjects: 108
Study: 38413458

Group type: EXPERIMENTAL
Intervention: nn-2D-IOUS
Number of subjects: 99
Study: 38413540

Group type: EXPERIMENTAL
Intervention: Intranasal DHE powder (STS101) 5.2 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal DHE powder (STS101) 7.0 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal DHE powder (STS101) 8.6 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular DHE mesylate 1.0 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Liquid nasal spray DHE 2.0 mg
Number of subjects: 36
Study: 38413587

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: DBS
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intracranial signals
Number of subjects: 57
Study: 38413796

Group type: EXPERIMENTAL
Intervention: Fulvestrant and everolimus
Number of subjects: 57
Study: 38413849

Group type: EXPERIMENTAL
Intervention: Chronic beta-blocker therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-beta-blocker therapy
Number of subjects: 106
Study: 38413871

Group type: EXPERIMENTAL
Intervention: High intraoperative mechanical power
Number of subjects: 218

Group type: COMPARATOR
Intervention: Traditional mechanical ventilation variables
Number of subjects: 218